cowen confer call aegean bunker fuel market impact imo
pleas click link regist call dial inform email
directli
pleas note regist call start time email sent dial
number appear directli screen hit submit
host
david epstein cfa credit cross capit analyst cowen
pleas see addendum report import disclosur
manag recap initi thought
given rel high expect investor believ result gener
solid manag care name coverag compani beat ep
report favor medic cost trend posit better expect outlook
set group strong would expect similarli
strong outlook ci close esrx deal
link full note
host second annual io summit begin societi
immunotherapi cancer annual meet washington
takeaway compani particip analyst led session follow
also summar main point close kol panel lesson learn io
link full note
rais fl estim pt follow check show significantli
improv full-pric sell trend america pt move ahead
result concern long-term growth margin structur keep us market
link full note
adjust estim reflect spin
introduc ep estim sotp price target
triniti remainco separ entiti assum growth
averag leas fleet higher interest expens manufactur margin
continu believ one best posit compani rail equipmnet
link full note
updat ordomet show take-two red dead redempt remain
lead widen distanc activis call duti black op ea
battlefield continu track well behind two lead titl
link full note
last week host meet paul oldham cfo edwin mok vice-president
strateg marketing/ir meet reinforc view strateg
posit strong cash balanc robust oper structur
trough oper margin industri servic busi expect
link full note
weekli highlight main takeaway result
affect wfe weak acmr good china exposur mobil test
weak smic season custom inventori work asml analyst day
potenti catalyst come week includ result cowen semi
semicap bu tour silicon valley
link full note
alna report review clinic progress updat upcom catalyst
first lead drug reloxalias fka enter hyperoxaluria eh
on-going top-lin second larger eh still track start ye
pend final fda talk primari hyperoxaluria/sever secondari
hyperoxaluria recent initi interim
link full note
consensu due execut misstep new transit haa
space busi posit workspac pipelin y/i hcm cross-sel
initi creat stronger set-up think asur may distract
acq believ issu fixabl still
attract organ playbook ahead lower pt
link full note
accord unsubstanti news articl athn like acquir taken
privat offer expect around roughli ev/ebitda
estim unsurpris given athn began strateg review process
earlier pressur activist investor offer provid attract
exit sharehold period uncertainti
link full note
weed report earn wednesday novemb confer call
et dial-in conserv model revenu mm
consensu mm think demand weed product
remain strong shipment like weight maintain outperform
link full note
weekend cldx present poster phase dose escal
studi solid tumor determin well toler
dose depend biolog effect line mediat activ
program continu expand base observ result date
link full note
continu growth commerci acceler growth continu drive
good growth legaci ci biggest catalyst next year esrx also
post solid core growth number rais pro-forma ep
ex-antm pt reiter
link full note
focu uveiti suffici
clearsid biomed report earn gave pipelin updat clsd
report neg result sapphir trial announc ceas xiper
combo eylea rvo dme focu uveiti file
year-end potenti approv
link full note
richemont cowen view premier global luxuri jewelri franchis
ep came expect weaker sale sept vs trend
higher expens includ one-tim expens relat
like strong jewelri sale momentum higher on-line penetr vs
prior see near-term headwind
link full note
hard reset rebuild confid
face long road improv execut consist manner rebuild
investor confid near-term catalyst appear limit potenti
need hit growth target potenti deal signal turn new busi
book updat pt reflect conserv estim vs guidanc
link full note
corvu report updat data alon plu atezolizumab
discuss result analyst event data show improv dcr
os combin arm compani also discuss biomark data support
adenosin pathway mechan tumor escap therapi
believ result support studi
link full note
present rapid-fir talk poster present clinic translat
data believ data consist previous
present data esmo demonstr proof mechan
probodi platform expect multipl clinic data readout
link full note
recent attend annual diabet technolog meet cgm new data
present clearli demonstr accurate/reli system
re-affirmed deserv premium price view plenti
interest updat relev describ herein
link full note
dicerna held investor event nyc highlight pipelin strategi discuss
phase dcr-phxc pivot ph program includ design detail potenti
pivot confirmatori trial well hbv candid advanc
poc studi
link full note
updat pro-forma estim reflect earn report
reiter market perform rate share price target goe
base increas estim adjust cost capit model
link full note
updat estim reflect chang
earn recent event
link full note
includ comp net restaur growth adj ebitda well estim
perhap concerningli freshii remov target comp
store system sale inabl provid
guidanc make us increasingli cautiou long-term stori
link full note
weak quarter ahead merger lower pt
given pend merger minim color given around qtr guidanc
issu analyst result lacklust w/ bill
miss street mln alongsid weaker deal flow issu could
market health intern execut deal paus due merger like rais
concern busi momentum merger pt
link full note
present multipl poster gave oral present enoblituzumab
pembrolizumab pt nave scchn nsclc report orr
respect view data increment posit
expect updat combin
link full note
melanoma pivot progress posit reveal- look
nktr updat featur full melanoma cohort ph pivot
trial demonstr deepen respons trend highlight
nivo combo appear well-posit rel nivo monotherapi
compar recent initi ph initi data tlr agonist
suggest combin activ io-refractori patient
link full note
phasebio lead candid revers agent anti-platelet drug
ticagrelor shown rapidli sustain revers effect
ticagrelor pivot phase ii studi track initi project
achiev world-wide sale think share
under-valued potenti
link full note
better-than-expect guidanc sent inexpens stock price-to-earnings
yield higher optimist progress made howev note
traction could stori per guidanc flat comp flat gross margin
slightli lower adj ebit execut priorit critic distract
customer-fac interact could lead disrupt
link full note
report earn updat on-going sad/mad trial lead
candid fulli enrol track releas interim data
poc trial start sma plan also present
encourag preclin result lead asset adjunct tx solid
tumor weekend
link full note
mcrb updat notabl commentari potenti revis
ecospor pivot trial design improv enrol affect
avail fmt appropri patient select toxin assay
look forward pivot trial start uc trial start io
updat could drive inflect sentiment
link full note
updat ep
modifi way model project concret adjust within forecast
continu rate share market perform price target
link full note
report earn pipelin updat cuti studi lead drug
tebipenem track start around clear posit pk/pd
data hand gram-neg potenti molecul like start clinic
test oral ntm agent final ind-en studi
link full note
multipl updat amber garnet cintrino updat
trso provid updat amber garnet cintrino trial initi
data combo dissapoint higher dose may show
improv appear similar competitor immutep
overshadow orr advanc melanoma
link full note
phase data track cvot underway
inclisiran program remain track includ reassur regard safeti
thu far idmc time data readout manag
outlin belief fund cash plu anticip mlnt
financ key object includ start cvot
link full note
tlri report earn tuesday novemb confer call et
dial-in model revenu mm in-lin consensu
find appropri conserv less maintain
link full note
yesterday sell-off revers today look excess given
offer first detail path posit cash howev sell yield
estimate cash flow still look earli step could durabl
improv
link full note
report strong result mostli expect across
board gross add continu acceler y/i quarter row
rais near-term estim modestli temper also move
conserv valuat stanc target price reiter
link full note
guidanc lower respons nt market headwind reiter op lt outlook
vive post better-than-anticip sale howev decreas full-year
revenu guidanc cite lengthier sale cycl stem caution among new
market entrant wake fda letter issu earli decreas
sale forecast along target think
market headwind clear next year reiter outperform
link full note
summari motion bid procedur stalk hors etc
follow entri interim order mercuria dip friday morn friday
night debtor file motion seek approv bid procedur entri
stalk hors mercuria etc cours almost certainli see respons
ad hoc notehold group futur certain aspect may chang
describ friday motion
link full note
midstat stock remain attract stand-alon basi
midstat earn gener posit believ compani well
posit gener meaning earn cash flow result lower futur
workov expens reduc capit expenditur higher averag oil price
thu creat valu sharehold still view midstat stock attract
stand-alone basi current valu ebitda
link full note
continu de-risk balanc sheet
ebitda beat consensu flat year/year nrp reduc leverag
debt remain well-cov asset longer trajectori continu
compel equiti tier capit structur becom maintain
posit bia debt
link full note
nov deutsch credit bureau focu
rep maxin water alreadi campaign ensur hous democrat make
chairman financi servic committe see elev chairman
inevit prioriti includ focu deutsch bank credit
bureau consum protect bureau miss act
cannabi terror risk insur act renew
link full note
miss financi hous cowenvis video
busi feder reserv week vice chairman randi quarl testifi
wednesday hous servic thursday senat bank chairman
jerom powel dalla fed thursday fed gov lael brainard speak
tuesday fintech big event senat judiciari hear tuesday big bank
link full note
next congress unlik get much accomplish legisl
chang leadership post key health care committe
announc come week worth note
link full note
import disclosur inform relat cowen washington research group
